Moser C - Search Results

1

Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha.

Mori A, Moser C, Lang SA, Hackl C, Gottfried E, Kreutz M, Schlitt HJ, Geissler EK, Stoeltzing O. Mori A, et al. Among authors: moser c. Mol Cancer Res. 2009 Aug;7(8):1390-8. doi: 10.1158/1541-7786.MCR-08-0525. Epub 2009 Aug 11. Mol Cancer Res. 2009. PMID: 19671674

2

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.

Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O. Lang SA, et al. Among authors: moser c. Mol Cancer Ther. 2007 Mar;6(3):1123-32. doi: 10.1158/1535-7163.MCT-06-0628. Mol Cancer Ther. 2007. PMID: 17363505

3

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.

Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, Stoeltzing O. Lang SA, et al. Among authors: moser c. Clin Cancer Res. 2007 Nov 1;13(21):6459-68. doi: 10.1158/1078-0432.CCR-07-1104. Clin Cancer Res. 2007. PMID: 17975158

4

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.

Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O. Moser C, et al. Mol Cancer Ther. 2007 Nov;6(11):2868-78. doi: 10.1158/1535-7163.MCT-07-0410. Mol Cancer Ther. 2007. PMID: 18025273

5

Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.

Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK, Stoeltzing O. Moser C, et al. Eur J Cancer. 2008 Jul;44(11):1577-86. doi: 10.1016/j.ejca.2008.04.003. Epub 2008 Apr 27. Eur J Cancer. 2008. PMID: 18445520

6

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.

Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O. Moser C, et al. BMC Cancer. 2008 Jul 23;8:206. doi: 10.1186/1471-2407-8-206. BMC Cancer. 2008. PMID: 18651980 Free PMC article.

7

Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.

Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O. Lang SA, et al. Among authors: moser c. Mol Cancer Ther. 2008 Nov;7(11):3509-18. doi: 10.1158/1535-7163.MCT-08-0373. Mol Cancer Ther. 2008. PMID: 19001434

8

Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.

Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler EK, Stoeltzing O. Hackl C, et al. Among authors: moser c. BMC Cancer. 2010 Dec 3;10:668. doi: 10.1186/1471-2407-10-668. BMC Cancer. 2010. PMID: 21129190 Free PMC article.

9

Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.

Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA. Taeger J, et al. Among authors: moser c. Mol Cancer Ther. 2011 Nov;10(11):2157-67. doi: 10.1158/1535-7163.MCT-11-0312. Epub 2011 Sep 1. Mol Cancer Ther. 2011. PMID: 21885862

10

Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors.

Moser C, Lang SA, Hackl C, Zhang H, Lundgren K, Hong V, McKenzie A, Weber B, Park JS, Schlitt HJ, Geissler EK, Jung YD, Stoeltzing O. Moser C, et al. Anticancer Res. 2012 Feb;32(2):427-37. Anticancer Res. 2012. PMID: 22287729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,090 results

Search Page

Filters